Publications by authors named "Paul H Gumerlock"

Claim this Profile
T
The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells.
Phillip R Purnell, Philip C Mack, Clifford G Tepper, Christopher P Evans, Tim P Green, Paul H Gumerlock

J Thorac Oncol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
Angela M Davies, Kari Chansky, Primo N Lara, Paul H Gumerlock, John Crowley

J Thorac Oncol· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impairment of the DNA repair and growth arrest pathways by p53R2 silencing enhances DNA damage-induced apoptosis in a p53-dependent manner in prostate cancer cells.
Hong-Lin Devlin, Phillip C Mack, Rebekah A Burich, Paul H Gumerlock, Hsing-Jien Kung

Mol Cancer Res· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
Angela M Davies, Christopher Ruel, Primo N Lara, Derick H Lau, Paul H Gumerlock

J Thorac Oncol· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation.
Christopher M Mahaffey, Angela M Davies, Primo N Lara, Brandi Pryde, William Holland, Paul H Gumerlock

Clin Lung Cancer· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spontaneous immortalization of human epidermal cells with naturally elevated telomerase.
Miguel A Rea, Lei Zhou, Qin Qin, Yann Barrandon, Karen W Easley, Paul H Gumerlock

J Invest Dermatol· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).
Primo N Lara, Kari Chansky, Angela M Davies, Wilbur A Franklin, Paul H Gumerlock

J Thorac Oncol· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer.
Angela M Davies, Cheryl Ho, Primo N Lara, Philip Mack, Paul H Gumerlock

Clin Lung Cancer· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.
Howard L West, Wilbur A Franklin, Jason McCoy, Paul H Gumerlock, Ralph Vance

J Clin Oncol· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
Primo N Lara, Walter M Stadler, Jeff Longmate, David I Quinn, Jason Wexler, Paul H Gumerlock

Clin Cancer Res· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
Primo N Lara, Mariana Koczywas, David I Quinn, Heinz Josef Lenz, Angela M Davies, Paul H Gumerlock

J Thorac Oncol· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy.
David R Gandara, Eric Vallières, Laurie E Gaspar, Karen Kelly, Kathy S Albain, Paul H Gumerlock

Clin Lung Cancer· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib-based combinations in the treatment of non-small-cell lung cancer.
Angela M Davies, Primo N Lara, Philip C Mack, Paul H Gumerlock, Richard J Bold

Clin Lung Cancer· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications.
Primo N Lara, Richard J Bold, Philip C Mack, Angela M Davies, Paul H Gumerlock

Clin Lung Cancer· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out?
David R Gandara, Paul H Gumerlock

J Clin Oncol· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.
Peter J Van Veldhuizen, James R Faulkner, Primo N Lara, Paul H Gumerlock, J Wendall Goodwin

Cancer Chemother Pharmacol· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial.
Primo N Lara, Philip C Mack, Timothy Synold, Paul Frankel, Jeff Longmate, Paul H Gumerlock

Clin Cancer Res· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial.
Primo N Lara, Lisa Y Law, John J Wright, Paul Frankel, Przemyslaw Twardowski, Paul H Gumerlock

Anticancer Drugs· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glycogen synthesis correlates with androgen-dependent growth arrest in prostate cancer.
Joachim B Schnier, Kayoko Nishi, Paul H Gumerlock, Frederic A Gorin, E Morton Bradbury

BMC Urol· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancement of radiation cytotoxicity by UCN-01 in non-small cell lung carcinoma cells.
Philip C Mack, Angela A Jones, Matthew H Gustafsson, David R Gandara, Paul H Gumerlock

Radiat Res· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial.
Primo N Lara, Paul H Gumerlock, Philip C Mack, Derick H M Lau, Regina Gandour-Edwards

Clin Lung Cancer· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition.
David R Gandara, Howard West, Kari Chansky, Angela M Davies, Derick H M Lau, Paul H Gumerlock

Clin Cancer Res· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy.
Tatsuo Kimura, Will S Holland, Tomoya Kawaguchi, Stephen K Williamson, Kari Chansky, Paul H Gumerlock

Ann N Y Acad Sci· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival and cell cycle kinetics of human prostate cancer cell lines after single- and multifraction exposures to ionizing radiation.
Susan L Scott, Paul H Gumerlock, Laurel Beckett, Yueju Li, Zelanna Goldberg

Int J Radiat Oncol Biol Phys· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.
Primo N Lara, Karen Giselle Chee, Jeff Longmate, Christopher Ruel, Frederick J Meyers, Paul H Gumerlock

Cancer· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis